Neuphoria Therapeutics (NEUP) Change in Receivables (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Change in Receivables for 4 consecutive years, with $495432.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Change in Receivables rose 4616.66% year-over-year to $495432.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 2048.77% increase from a year earlier, with the FY2025 full-year figure at -$114936.0, up 61.59% from the prior year.
• Change in Receivables was $495432.0 for Q1 2026 at Neuphoria Therapeutics, down from $1.1 million in the prior quarter.
• Over five years, Change in Receivables peaked at $1.1 million in Q4 2025 and troughed at -$326992.0 in Q4 2023.
• A 4-year average of $107204.8 and a median of -$10190.0 in 2025 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables tumbled 167.22% in 2024 and soared 4616.66% in 2026, its largest moves.
• Over 4 years, Change in Receivables stood at -$326992.0 in 2023, then soared by 75.41% to -$80399.0 in 2024, then soared by 1478.31% to $1.1 million in 2025, then slumped by 55.29% to $495432.0 in 2026.
• The last three Change in Receivables figures came in at $495432.0 (Q1 2026), $1.1 million (Q4 2025), and -$10190.0 (Q3 2025), per Business Quant data.